Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

28.07 1.31 −4.46%
Market cap
$6.9B
P/E
0.0×
Fwd P/E
−213×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

94.53 56.96 0.00 0.00
P/S ratio
5.81 3.11 2.00 3.12
P/FCF ratio
95.88 98.76 59.47 96.77
P/Operating CF
86.33 119.14 53.05 (223.56)
P/B ratio
22.10 13.50 10.63 24.79
EV/Sales
5.96 3.28 2.09 3.32
EV/EBITDA
83.39 47.35 118.84 0.00
EV/FCF
98.43 104.10 62.27 103.09
Current Ratio
1.88 1.90 1.69 0.93
Net Debt/EBITDA
11.41 13.96 (4.08) (7.97)
Debt/Equity
1.67 1.80 2.18 4.21
Earnings Yield
1.06% 1.76% (0.24%) (1.76%)
Free Cash Flow Yield
1.04% 1.01% 1.68% 1.03%
Free Cash Flow per Share
0.37 0.01 0.26 (0.27)
Book value per Share
2.57 2.40 1.95 1.40
Free Cash Flow
83.46 1.92 59.51 (61.86)
EV/EBIT
114.58 72.90 0.00 0.00
Other line items

Show all line items

Columns are period end dates